{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:52:21Z","timestamp":1788871941535,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T00:00:00Z","timestamp":1395705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Genentech\/Roche"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,6,15]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The authors examined the \u201creal\u2010world\u201d effectiveness of rituximab (R) maintenance therapy (R\u2010maintenance) compared with observation after R\u2010based induction therapy in patients with previously untreated follicular lymphoma (FL) in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The National LymphoCare Study is a prospective, multicenter, observational study that enrolled\u2009&gt;\u20092700 untreated patients with FL diagnosed from 2004 to 2007 at 265 sites in the United States. Among these, patients who achieved at least stable disease after R\u2010based induction therapy were eligible for the current analysis. Patients who initiated R\u2010maintenance within 215 days of completing induction therapy were categorized as the R\u2010maintenance group, and those who did not initiate therapy during this period were categorized as the observation group. The objective of the current study was to determine the effect of R\u2010maintenance on progression\u2010free survival (PFS), time to next treatment (TTNT), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A total of 1439 patients completed R\u2010based induction therapy, 1186 of whom met all inclusion criteria (541 patients received R\u2010maintenance and 645 patients were observed). Characteristics that were found to be predictive of receiving R\u2010maintenance were histology grade (1\/2), Ann Arbor stage of disease (III\/IV), geographic region (region other than the West), and practice setting (community practice). With a median follow\u2010up of 5.7 years, R\u2010maintenance was associated with superior PFS (hazards ratio [HR], 0.68; 95% confidence interval [95% CI], 0.56\u20100.84 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.0003]) and TTNT (HR, 0.66; 95% CI, 0.52\u20100.84 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.0007]). No significant difference in OS was observed (HR, 0.81; 95% CI, 0.58\u20101.14 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.23]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      R\u2010maintenance in patients with FL and at least stable disease after R\u2010based induction therapy provided significantly longer PFS and TTNT in comparison with observation, but no significant difference in OS was observed with 5\u2010years of follow\u2010up. This comparative effectiveness study aligns with the results of randomized trials suggesting that similar outcomes occur with R\u2010maintenance in FL with the treatment variations observed in clinical practice.\n                      <jats:bold>\n                        <jats:italic>Cancer<\/jats:italic>\n                        2014;120:1830\u20131837\n                      <\/jats:bold>\n                      . \u00a9 2014 The Authors.\n                      <jats:italic>Cancer<\/jats:italic>\n                      published by Wiley Periodicals, Inc. on behalf of\n                      <jats:italic>American Cancer Society<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.28659","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T10:48:05Z","timestamp":1395744485000},"page":"1830-1837","source":"Crossref","is-referenced-by-count":34,"title":["The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States"],"prefix":"10.1002","volume":"120","author":[{"given":"Loretta J.","family":"Nastoupil","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Sinha","sequence":"additional","affiliation":[{"name":"Pinnacle Heath Systems Harrisburg Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Byrtek","sequence":"additional","affiliation":[{"name":"Genentech\/Roche South San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Biostatistics RTI Health Solutions Research Triangle Park North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Genentech\/Roche South San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"James P. Wilmot Cancer Center University of Rochester Rochester New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"Holden Comprehensive Cancer Center, University of Iowa Iowa City Iowa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Cerhan","sequence":"additional","affiliation":[{"name":"Department of Health Sciences Research Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Dawson","sequence":"additional","affiliation":[{"name":"Genentech\/Roche South San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology and Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_7_3_1","first-page":"4","article-title":"Classification updates and clinical investigations in indolent non\u2010Hodgkin lymphoma","volume":"6","author":"Cheson BD","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"e_1_2_7_4_1","first-page":"75","article-title":"Natural history of and therapy for the indolent non\u2010Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.97.97","article-title":"A comparison of the effectiveness of first\u2010line chemoimmunotherapy regimens for follicular lymphoma (fl) used in the United States [abstract]","volume":"118","author":"Nastoupil L","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.140"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021113"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.LBA-6.bld0076_P3_LBA-6","article-title":"Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): a randomized phase III study comparing 2 different rituximab dosing strategies for low tumor burden follicular lymphoma [abstract]","volume":"118","author":"Kahl B","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00600.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00601.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00602.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28659","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.28659","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:59:39Z","timestamp":1760277579000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,25]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,6,15]]}},"alternative-id":["10.1002\/cncr.28659"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28659","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,25]]}}}